Tab: Acyclovir (Zovirax) oral formulations are indicated for the treatment of herpes simplex virus infections of the skin and mucous membranes including initial and recurrent genital herpes.
Acyclovir (Zovirax) oral formulations are indicated for the suppression (prevention of recurrences) of recurrent herpes simplex infections in immune-competent patients.
Acyclovir (Zovirax) oral formulations are indicated for the prophylaxis of herpes simplex infections in immune-compromised patients.
Acyclovir (Zovirax) oral formulations are indicated for the treatment of varicella infections (chicken-pox) and herpes zoster (shingles). Studies have shown that early treatment of shingles with Acyclovir (Zovirax) has a beneficial effect on pain and can reduce the incidence of post-herpetic neuralgia (zoster-associated pain).
Acyclovir (Zovirax) oral formulations are indicated for the management of certain severely immunocompromised patients, namely those with advanced HIV disease (CD4+ counts <200/mm3, including patients with AIDS or severe ARC) or following bone marrow transplantation. Studies have shown that oral Acyclovir (Zovirax) given in conjunction with antiretroviral therapy (mainly oral RETROVIR) reduced mortality in patients with advanced HIV disease and that oral Acyclovir (Zovirax) preceded by one month's treatment with intravenous Acyclovir (Zovirax) reduced mortality in bone marrow transplant recipients. In addition, oral Acyclovir (Zovirax) provided effective prophylaxis for herpes virus disease.
Powd for infusion: Acyclovir (Zovirax) i.v. for infusion is indicated for the treatment of herpes simplex infections.
Acyclovir (Zovirax) i.v. for infusion is indicated for the prophylaxis of herpes simplex infections in immune-compromised patients.
Acyclovir (Zovirax) i.v. for infusion is indicated in the treatment of varicella zoster infections.
Acyclovir (Zovirax) i.v. for infusion is indicated for the treatment of herpes simplex infections in the neonate.
Other Services
Country
Account